Podcasts about biotech

Join us for an exciting episode of The Alexei ZamyatinEdge of Show, live from ECC 8 in Cannes! In this episode, Tom Vieira from Coinbase explores how Coinbase is approaching on-chain identity and infrastructure, and why developer experience is at the heart of crypto's next growth cycle. Next Alexei Zamyatin from BOB breaks down Bitcoin-secured rollups, explaining how BOB is merging the strengths of Bitcoin and Ethereum to create a hybrid ecosystem and finally Kenneth Shek from Moca Network shares how Museum of Crypto Art is evolving as a cultural hub, curating digital art and expanding the role of creators in the decentralized era.Don't miss this insightful conversation packed with expert perspectives on the future of Bitcoin, DeFi, and the broader crypto ecosystem!Support us through our Sponsors! ☕

The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

TODAY ON THE ROBERT SCOTT BELL SHOW: CHD Lawsuit, Vax Task Force, Jeffrey Adam, RFK Biotech Backlash, Lapis Albus, Meds Stealing Minds, MAHA Lunch Wars, Wiles Saves Prasad, Global Vax Shift, HepB Infant Vaccines, Zombie Rabbits and MORE! https://robertscottbell.com/chd-lawsuit-vax-task-force-jeffrey-adam-rfk-biotech-backlash-lapis-albus-meds-stealing-minds-maha-lunch-wars-wiles-saves-prasad-global-vax-shift-hepb-infant-vaccines-zombie-rabbits-and-more/ https://boxcast.tv/view/vax-task-force-jeffrey-adam-rfk-biotech-backlash-lapis-albus-meds-stealing-minds-maha-lunch-wars-zombie-rabbits---the-rsb-show-8-15-25-f9tr3kdg8vlmprvhxcre Please read this disclaimer carefully before you (“you”, “your”) use our [Your Website URL] website (“website”, “service”) operated by the [Your Business Name] (“operator”, “us”, “we”, “our”). Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Listen & subscribe on Apple, Spotify, YouTube, and other platforms. Welcome everyone to the weekly San Diego Tech News! I'm Neal Bloom from Rising Tide Partners and the Tacos and Tech Podcast. My co-host in this episode is Fred Grier, journalist and author of The Business of San Diego substack. He covers the ins-and-outs of the startup world including breaking news, IPOs, fundraising rounds, and M&A through his newsletter. Before we dive in, we wanted to thank and ask our listeners to help us grow the show, leave a review and share with one other person who should be more plugged in with the SD Tech Scene. Thank you for the support and for helping us build the San Diego Startup Community!   Aug 15 SDEE event debrief Biotech layoffs: Thermo, Poseida Therapeutics Equillium raise Scale Bio acquired by 10X Genomics Plantible opens a 100-acre manufacturing module in Texas BAE Shipyard Gains Defense Build Contracts Prebys Foundation Donates $1M to support grant medical research   Curated Events List – For full list – check The Social Coyote Defense Tech Build Day - Aug 28 Gaming Gathering Build Day - Sept 2 SD Defense at SoCal Deep Tech Week - Sept 16

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Claire Riches, Vice President, Clinical Solutions at Citeline. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering: Being involved in the clinical development and commercial launch of a little mega-blockbuster, called... Viagra. Her first exposure to outsourcing at a small biotech, and the importance of partnerships in progressing the pipeline. Ignoring the pharma industry snobbery, and opting to move into the fast and varied world of CROs. Timeless sponsor and provider partnership tips, including the importance of aligned intentions, especially with biotechs. How are the tailwinds for rare diseases, meeting unmet patient needs, AI/data, and personalised medicines driving demand at Citeline? With over 30 years' experience in the life science sector, Claire is a passionate advocate of bringing drug development to life. Having worked in large pharma, biotech and the CRO space, Claire uses her platform to raise awareness of the challenges the industry is facing, and how as a collective voice, we can solve big, challenging questions. She believes strongly in the need to ask questions of the industry to drive change, which in turn drives innovation and growth. Claire speaks regularly through various forums on the topics of Women in Science, Impacts of Politics and Economics on Drug Development and Drug Access, and Evolution and Efficiency of Drug Development pathways. She is currently focused on levelling the playing field for the Biotech industry via her podcast Small Biotech, Big Decisions | Citeline   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Synopsis: Some of the most game-changing ideas in healthcare come from unexpected intersections—where engineering meets biology, and where data meets patient urgency. This episode of Biotech 2050 dives into that exact convergence with a look at how one visionary leader helped pioneer blood-based cancer diagnostics. Co-CEO & Co-Founder of Guardant Health, AmirAli Talasaz, shares the story behind building one of biotech's most impactful companies. From a graduate student navigating genomics for the first time to raising over $3 billion and leading a public company, he reflects on lessons learned, obstacles faced, and what it takes to create a patient-first culture at scale. The conversation explores the technology behind liquid biopsies and companion diagnostics, the challenges of insurance reimbursement, and how Guardant's innovations are helping detect recurrence and screen for early-stage cancers—all through a simple blood test. Hosted by Biotech 2050 Co-Founder Rahul Chaturvedi, this episode is packed with insights on biotech leadership, pharma partnerships, and building a company that scales with both urgency and heart. Biography: AmirAli Talasaz is the co-CEO of the leading precision oncology company, Guardant Health, which he co-founded in 2012 with Helmy Eltoukhy. Prior to co-founding Guardant Health, he was senior director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next-generation genomic analysis. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. Talasaz received his PhD in electrical engineering and MSc in management science from Stanford University.

"The whole environment of the company is about discovery and innovation, so it's really buzzing with energy." In this episode of The Biotech Startups Podcast, Samir Khleif reveals how he took Georgiamune from vision to reality—building a top-tier team, advancing a pipeline of novel drugs, and keeping innovation at the company's core. Host Jon Chee explores what sets Georgiamune apart, as Samir opens up about navigating the pitfalls of fundraising, the shift from academia to entrepreneurship, and why transparency and self-awareness are crucial for success in biotech leadership.

Join us for an exciting episode of The Edge of Show sponsored by SuperWorld featuring Hrish Lotlikar, the co-founder and CEO of SuperWorld! In this episode, we dive deep into the innovative world of virtual real estate and how it can have real-world utility.Discover how SuperWorld is redefining land ownership in the metaverse, the upcoming token launch with Republic, and the potential for staking to turn virtual properties into revenue-generating assets. Rish shares insights on the future of augmented reality, premium property staking, and how anyone can create their own unique world within SuperWorld.We also explore the various use cases for SuperWorld, from travel recommendations to real-world assets and events, and how users can earn by creating and sharing their maps. Plus, get a sneak peek into the demo of purchasing land within SuperWorld!Join the SuperWorld Whitelist for Early Access to $SPWR https://www.superworldapp.com/token?uniqueID=am9zaEBlZGdlb2YueHl6 Support us through our Sponsors! ☕

In this episode, Jacob sits down with Joshua Meier, co-founder of Chai Discovery and former Chief AI Officer at Absci, to explore the breakthrough moment happening in AI drug discovery. They discuss how the field has evolved through three distinct waves, with the current generation of companies finally achieving success rates that seemed impossible just years ago.  The conversation covers everything from moving drug discovery out of the lab and into computers, to why AI models think differently than human chemists, to the strategic decisions around open sourcing foundational models while keeping design capabilities proprietary. It's an in-depth look at how AI is fundamentally changing pharmaceutical innovation and what it means for the future of medicine. Check out the full Chai-2 Zero-Shot Antibody report linked here: https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf [0:00] Intro[2:10] The Evolution of AI in Drug Discovery[6:09] Current State and Future of AI in Biotech[11:15] Challenges and Modalities in Therapeutics[15:19] Data Generation and Model Training[23:59] Open Source and Model Development at Chai[28:35] Protein Structure Prediction and Diffusion Models[30:57] Open Source Models and Their Impact[35:41] How Should Chai-2 Be Used?[39:34] The Future of AI in Pharma and Biotech[43:51] Key Milestones and Metrics in AI-Driven Drug Discovery[48:24] Critiques and Hesitation[55:06] Quickfire With your co-hosts: @jacobeffron - Partner at Redpoint, Former PM Flatiron Health @patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn @ericabrescia - Former COO Github, Founder Bitnami (acq'd by VMWare) @jordan_segall - Partner at Redpoint

HEADLINES:♦ Abu Dhabi HR Expert Warns Against Including Nafis Allowance in Salary Packages♦ Saudi Cousins' Base Boon Salon Creates Georgina Rodríguez's Engagement Nail Look♦ Mubadala Capital Ventures Joins $30M Funding Round for US Biotech Tahoe Therapeutics♦ Binghatti Holding's $500 Million Sukuk Debuts Strong on London Stock Exchange Newsletter: https://aug.us/4jqModrWhatsApp: https://aug.us/40FdYLUInstagram: https://aug.us/4ihltzQTiktok: https://aug.us/4lnV0D8Smashi Business Show (Mon-Friday): https://aug.us/3BTU2MY

As the lead wreaks havoc on Cooper's development, Shannon searches for answers. Desperate to get a handle on what was happening to her son, she grabs onto a lifeboat - nursing school. Andy tries to piece together the past to make sense of the present.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper BurkettEP2 features Keith Nobbs and Frank Wood. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The key to conquering autoimmune diseases and type 1 diabetes may lie not in replacing lost cells, but in retraining the immune system using cells already within the body.Biotech is increasingly exploring stem cell therapies, but a quieter revolution is brewing: stromal cell therapy. These master “coordinators” aren't about rebuilding tissues molecule by molecule - instead, they orchestrate an anti-inflammatory response, offering new hope for conditions once considered incurable.In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Lindsay Davies, a leading expert in advanced therapies. She is the CSO at NextCell Pharma, consultant at CellTherEx, and co-founder of QVance, a QC analytics provider for ATMPs. Recently elected Vice President Elect for Europe at ISCT, Lindsay also chairs its European Industry Committee and serves on multiple task forces. With over 20 years bridging academia and industry, she's helped shape the full lifecycle of cell-based therapies, from development to commercialization.Here are three reasons why you can't miss this episode:Stromal Cells - The Unsung Heroes: Discover the essential distinction between stem cells (the “builders”) and stromal cells (the “coordinators”), and how harnessing the latter's unique immune-modulatory powers is unlocking treatments for diabetes, COVID-19, and autoimmune diseases.A Manufacturing Mindset Shift: Lindsay explains why scaling out cell therapies defies the “plug-and-play” approaches of traditional biologics manufacturing. With cell quality so sensitive to environmental shifts, the key lies in process simplicity, early regulatory collaboration, and deep biological understanding - especially when donor variability enters the mix.Allogeneic Therapies Made Real: Thanks to umbilical cord-derived stromal cells, treatments can be manufactured at scale, stored frozen, and delivered on demand - no patient matching required. The result? Outpatient infusions, no side effects, and effects lasting up to five years, dramatically simplifying lives for those with chronic inflammatory conditions.Ready to rethink how cell therapies are changing medicine - and what it could mean for your bioprocessing strategy? Hit play and find out how Lindsay Davis is redefining what's possible in advanced therapy manufacturing.Connect with Lindsay Davis:LinkedIn: www.linkedin.com/in/lindsay-c-daviesWebsite: www.nextcellpharma.comIf you're interested in breakthroughs in cell therapy, here's what some of our previous guests have shared from the front lines of innovation:Episodes 105-106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver KraemerEpisodes 109-110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier DetournayEpisodes 125-126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiNext step:Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest anJoin 500+ CGT leaders at Advanced Therapies Europe 2025 (September 2-4, Barcelona) for live case studies, regulatory insights, and exclusive collaboration opportunities. As a Smart Biotech Scientist listeners you'll save 20% with code SMARTPODCAST20 – Register hereSupport the show

Live from EthCC Cannes, this sponsored Edge of Show by Ammalgam brings together three trailblazers building the infrastructure for Web3's next leap forward. First, Marc Boiron, CEO of Polygon Labs, shares how Polygon is tackling scalability, interoperability, and the drive toward a unified Web3 ecosystem. Next, Rebecca Liao From, Head of Ecosystem at Saga, reveals how Saga's chainlets are unlocking customizable, high-performance blockchain environments for developers worldwide. Finally, Jordan Jefferson, Founder of DogeOS, takes us inside the playful yet powerful vision for a meme-driven operating system that merges community culture with serious blockchain innovation.From cross-chain solutions to developer empowerment and the rise of niche blockchain platforms, this conversation offers a clear view of how the next internet is being built—right now.Don't forget to like, subscribe, and hit the notification bell for more insights from the cutting edge of technology!Support us through our Sponsors! ☕

We love to hear from our listeners. Send us a message. On this week's episode, Bill Holodnak, Cofounder and CEO of Occam Global, a life sciences executive recruitment firm (and occasional investor), shares insights from his decades of experience pairing executives with drug development companies, and talks about the psychology of successful biotech leadership. From building an advisory board to the sequencing of executive hires, such as CSOs, CMOs, CBOs, and CFOs, as a company grows, Holodnak offers specific tips to help founders and investors create leadership teams capable of winning the "slow motion roulette" business of biotech.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

What happens when a rare disease diagnosis changes everything? When you're told your child will never walk, never talk. On this episode, we learn about Rett Syndrome and sit down with a parent who became his daughter's fiercest champion and a patient advocate committed to giving these families hope. Join us for an inspiring conversation about finding strength, building community, and living life to the fullest.To go behind the scenes and learn more about this episode, visit “Turning Pain Into Purpose: Advocating for Families with Rett Syndrome.”Thanks for listening! We're now on YouTube- follow us here. To receive episode updates and bonus material, subscribe to our mailing list here.

El sargazo sigue llegando a las costas de la República Dominicana, afectando playas, turismo y salud pública, mientras las autoridades parecen ir a paso lento. Conversamos con Elena Martínez Martínez, cofundadora de SOS Biotech y reconocida por el príncipe de Mónaco por su lucha contra este desastre ambiental. Hablamos sobre la situación actual del sargazo en el país, el proyecto de ley impulsado por el senador Rafael Duluc, y las soluciones urgentes que podrían evitar el colapso de nuestra industria turística.

Send us a textIn this episode of the Life Science Success Podcast my guest is John Schmitt, a military veteran, entrepreneur, and Co-Founder & CEO of iXpressGenes who is leveraging innovative RNA biomarker technologies to revolutionize trauma screening in healthcare. With over 20 years of leadership experience in the U.S. Army and a Master's degree in Microbiology and Immunology, John is dedicated to developing data-driven solutions for early detection and prevention of trauma-related diseases.00:00 Introduction and Podcast Overview01:02 Welcoming the Guest: John Schmitt02:00 John Schmitt's Journey to Biotechnology05:58 Military Experience and Leadership Insights13:09 Founding  iXpressGenes: The Origin Story17:31 Mission and Objectives of iXpressGenes23:08 Challenges and Innovations in Biomarker Technologies27:42 Personal Leadership and Inspirations35:00 Conclusion and Podcast Wrap-Up

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Eli Lilly is facing significant drug pricing pressure, with issues ranging from the pricing of their weight loss pill Orfoglipron to market battles with competitors like Novo Nordisk. Despite the challenges, Lilly's executives see opportunities for their products in the real world. Jazz Pharmaceuticals received FDA approval for Dordaviprone, making it the first new treatment for an ultra-rare brain tumor. In other news, Sarepta beat Q2 estimates despite not holding an investor call, and Trilink Biotechnologies is offering process development services for nucleic acid therapeutic development. Lotte Biologics is expanding its global CDMO operations, while a big pharma-backed mRNA startup raised $153 million in funding. Novo Nordisk's new CEO is focusing on obesity and diabetes, Pfizer is in talks with Trump on most favored nation drug pricing, and Bayer expects more layoffs. These developments in the pharma and biotech world showcase the ongoing challenges and opportunities in the industry. Stay tuned for more updates on the latest news and trends in this rapidly evolving sector.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novo Nordisk's new CEO, Maziar Mike Doustdar, is focusing on developing more drugs for obesity and diabetes while trimming the company's pipeline. The Department of Health and Human Services is terminating around $500 million in contracts for mRNA vaccine development, affecting companies like Moderna and Pfizer. Chinese biotechs are turning to big pharma for partnerships to survive, while Trilink Biotechnologies offers process development services for nucleic acid therapeutic development. Other top stories include biopharma CEOs being pulled into policy discussions, Bayer expecting more layoffs, and Trump threatening high tariffs on pharmaceuticals. The industry is also seeing investments in future technologies and strategies, such as AI for real-world research and integrated supply chain strategies for pharma manufacturing.Big pharma is providing support to struggling Chinese biotech companies by out-licensing drugs to multinational corporations. The recent increase in deals highlights the potential for partnerships with biotechs in the region. Biopharma CEOs are facing policy questions from tariffs to drug pricing, impacting their second quarter earnings calls. AI can help pharmaceutical companies adapt to policy pressures in the regulatory environment. Big pharmas are investing in incubators and venture funds to uncover scientific trends and determine future focus points. Pfizer's CEO is in contact with the President over drug pricing policies, while Moderna is focused on R&D partnerships rather than mergers and acquisitions. Novo's new CEO is emphasizing execution in obesity and diabetes research while trimming their pipeline. Biontech is committing to infectious diseases amid concerns over vaccine demand. Trump's threat of high pharma tariffs, a surge in July layoffs, and legal battles between Moderna, Pfizer, and Biontech are also making headlines. Events on AI for real-world research and integrated supply chain strategies for pharma manufacturing are upcoming, along with job opportunities in biostatistics, manufacturing, and publications.

What if the internet wasn't a series of disconnected websites and apps—but a fully immersive, persistent world where millions of people could connect, build, and interact in real time?In this sponsored episode by RP1 of The Edge of Show, we dive into the revolutionary work of RP1, a team building the infrastructure for the next era of the internet. Sean Mann and Dean Abramson share their mission to replace today's fragmented virtual experiences with a seamless, ultra-scalable, browser-based metaverse—capable of supporting millions of concurrent users on a single shard.We explore:How RP1 achieves real-time rendering and voice for massive crowdsWhy interoperability is key to breaking platform silosThe technical breakthroughs behind their open metaverse protocolHow developers, brands, and users can plug into this living digital layerThis isn't a game. It's the blueprint for a new internet—and it's already working.If you care about spatial computing, Web3, or the future of digital infrastructure, this episode is a must.Support us through our Sponsors! ☕

How can biotech companies stay resilient and competitive when public sector funding becomes unpredictable? In this episode, host James Zanewicz, JD, LLM, RTTP, sits down with Adeyinka “Adey” Pierce-Watkins, MS, PMP—Director of Biodefense and Government Contracting at BDO USA—for a timely conversation on surviving and thriving in today's evolving federal funding landscape. From defense contracts to international partnerships, Adey shares practical guidance for life science leaders aiming to tap into strategic public funding opportunities. In this episode, you'll learn: How to identify and access alternative funding sources—including state, federal, and international opportunities. What biotech organizations need in place to be “government-ready” for grants, contracts, and urgent response funding. Why strategic planning, partnerships, and compliance infrastructure are essential to winning and executing federal awards. Whether you're pursuing BARDA grants, entering international consortia, or rethinking your risk exposure, this episode offers actionable insights to help biotech innovators chart a smarter path forward. Links: Connect with Adey Pierce, MS, PMP, and check out BDO USA. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about the Cancer Prevention & Research Institute of Texas, TEDCO, and the California Institute for Regenerative Medicine. Learn more about Flagship Pioneering, Andreessen Horowitz, Novartis, Johnson & Johnson, and Roche. Learn more about HERA, Horizon Europe, AMED, and A*STAR. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

What if your love for playing hockey was the very thing that kept you from your dream of a military career? Well, if you're Matt Dylewski, you pivot and use your technology smarts to create 3-D printed prosthetics for injured veterans, proving there's more than one way to serve.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Breaking News: Pfizer announces successful COVID-19 vaccine trialsIn a groundbreaking announcement, Pfizer revealed that their COVID-19 vaccine candidate has shown to be over 90% effective in preventing the virus. This news brings hope to the world as we continue to battle the global pandemic.##FDA approves new treatment for Alzheimer's diseaseThe FDA has approved a new treatment for Alzheimer's disease, marking a significant advancement in the fight against this debilitating condition. This approval could potentially change the lives of millions of patients and their families.##Johnson & Johnson recalls baby powder due to asbestos contaminationJohnson & Johnson has issued a voluntary recall of its baby powder products after trace amounts of asbestos were found in samples. This news has raised concerns about the safety of talc-based products and the potential risks they pose to consumers.##Novartis announces major breakthrough in cancer researchNovartis has made a significant breakthrough in cancer research with the development of a new targeted therapy that has shown promising results in clinical trials. This innovation has the potential to revolutionize cancer treatment and improve outcomes for patients.##Merck receives FDA approval for new diabetes drugMerck has received FDA approval for a new diabetes drug that offers another option for patients struggling to manage their condition. This approval expands treatment options and provides hope for those living with diabetes.##Roche acquires biotech company in multi-billion dollar dealRoche has announced the acquisition of a biotech company in a multi-billion dollar deal that will expand its portfolio and strengthen its position in the market. This strategic move demonstrates Roche's commitment to innovation and growth in the biotech sector.##Incyte collaborates with academic research center to develop new therapiesIncyte has formed a collaboration with an academic research center to develop new therapies for a range of diseases, including cancer and inflammatory conditions. This partnership brings together expertise from both sectors to accelerate the discovery and development of innovative treatments.##Overall, these recent developments in the pharmaceutical and biotech industry highlight the ongoing efforts to advance healthcare and improve patient outcomes. From groundbreaking vaccines to innovative therapies, these advancements are shaping the future of medicine and providing hope for patients worldwide.

This week on Careers in Discovery, we're joined by Martin Brenner, CEO and CSO of iBio and one of Biotech's most experienced R&D leaders. Martin shares his journey from pharmacologist to global R&D executive, with leadership roles at Pfenex, Recursion, AstraZeneca, and Stoke Therapeutics. Now at iBio, he leads a company developing gene therapies for rare diseases - while applying lessons from decades of drug development to a new generation of science. We talk about the power of simplicity in communication, why leaders need to create space for science to breathe, and how to build R&D teams that are lean, smart, and focused on what matters most.

A mysterious dust fills a young family's apartment. The truth begins to unravel when the mother gets a call from the pediatrician - the monster deep within the walls has been unleashed. LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett. EP1 features Zak Orth, Jenny Maguire, Daphne Gaines, and Micheal Gaston. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

How do researchers keep our dirt clean? How can earthworms, duckweed, birds and bees help us ensure environmental safety? Find out now by listening in with our experts from Charles River's Hungarian site - Szabolcs Gáty and David Esdaile.

Dr Murali Ramachandra, CEO of Aurigene Oncology, talks to Anju Ghangurde about the tough biotech funding environment, promising pipeline assets including a CAR-T cell therapy in Phase II and ‘hybrid' manufacturing options, besides outcome-based reimbursement models. The promise of bispecifics and multispecifics in oncology, including Chinese biotech Akeso's PD-1/VEGF bispecific antibody, are some of the other topics he discussed.

What if biotech's biggest scaling challenge isn't technical—but philosophical? In this episode, Massimo Portincaso, founder and CEO of Arsenale Bioyards, explains why industrial biotech must be reimagined from the ground up. He challenges legacy “scale-up” thinking, highlighting biology's context dependency and the economic dead ends of retrofitted pharma models. From modular, AI-informed bioreactors to a scale-out strategy and data-first infrastructure, Massimo shares how his team is rewriting the rules of economic viability, manufacturing innovation, and organizational design. Discover why scaling out — not up — is the future of biomanufacturing.--- Hey Climate Tech enthusiasts! Searching for new podcasts on sustainability? Check out the Leaders on a Mission podcast, where I interview climate tech leaders who are shaking up the industry and bringing us the next big thing in sustainable solutions. Join me for a deep dive into the future of green innovation exploring the highs, lows, and everything in between of pioneering new technologies.Get an exclusive insight into how these leaders started up their journey, and how their cutting edge products will make a real impact. Tune in on…YouTube: https://www.youtube.com/@leadersonamissionNet0Spotify: https://open.spotify.com/show/7o41ubdkzChAzD9C53xH82Apple Podcasts: https://podcasts.apple.com/us/podcast/leaders-on-a-mission/id1532211726…to listen to the latest episodes!Timestamps:00:46 - Biology resists code scaling03:18 -  From BCG to biotech founder07:33 -  Why biotech remains niche10:24  - Redesigning from first principles13:40 -  Biology's context dependency16:55  - Intelligent design via Bayesian models18:46 -  Building the bioproduction stack21:00 -  Scale-out vs scale-up25:56 -  Rethinking the CDMO model29:20 -  Reinventing the capital stack33:30 -  Future sectors & applications37:10 -   Killing the org chart40:12 -  Complexity as a strategic assetUseful links: Arsenale Bioyards website: https://arsenale.bio/Arsenale Bioywards LinkedIn: https://www.linkedin.com/company/arsenale-bioyards/Massimo Portincaso LinkedIn: https://www.linkedin.com/in/massimo-portincaso-36a8795/Leaders on a Mission website: https://cs-partners.net/podcasts/Simon Leich's LinkedIn: https://www.linkedin.com/in/executive-talent-headhunter-agtech-foodtech-agrifoodtech-agritech/

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. BioNTech is focusing on infectious diseases as vaccine rates drop, with expectations that the US COVID-19 vaccination rate will decrease slightly. Glioblastoma research is seeing increased funding and interest from companies like Merck and Jazz Pharmaceuticals. The FDA's rejection of Replimmune's melanoma drug, despite staff consensus, has caused a drop in the company's stock. Sarepta and Capricor learned of regulatory decisions through media leaks, causing confusion for patients and families. Trilink Biotechnologies offers process development services for nucleic acid therapeutic development. Lotte Biologics is expanding globally, Allogene is discontinuing an immunosuppressive antibody after a patient death, and NIH funding cuts are impacting biotech. Pharmas are increasing investment in AI despite challenges in the industry. Trump urges pharma companies to address drug pricing, while Merck plans to cut 6,000 jobs to save $3 billion.

In this episode of FEG's Insight Bridge Podcast, Greg Dowling speaks with Peter Kolchinsky, Managing Partner at RA Capital. Together they delve into the drivers and details of today's biotech industry, how to foster innovation and why Peter is optimistic about biotech's ability to address autoimmune disorders. Peter shares RA Capital's investment approach, which emphasizes patience, rigor and selectiveness across healthcare and life science sectors.You can find every episode of FEG Insight Bridge podcasts in one place and sign up to receive our other publications here.

Live from Proof of Talk Paris 2025, this episode of The Edge of Show explores the evolution of digital finance, security, and real-world blockchain utility with four visionary leaders shaping the next phase of Web3.First, we spoke with Stephan Lutz, CEO of BitMEX, who shared insights on exchange security, AI-assisted trading, and how BitMEX is navigating a more responsible approach to token listings and trader education.Next, we sat down with Nkiru Uwaje, CEO of Mansa, to learn how her team is powering cross-border payments with stablecoins and building liquidity rails for Africa, Southeast Asia, and Latin America.Then we spoke with Jason Jiang, Chief Business Officer at CertiK, who outlined how real-time monitoring and smarter compliance tools are transforming security in blockchain—and why regulators are finally catching up.Lastly, Damu Winston from Amazon Web3 joined us to discuss the convergence of Web3, AI, and spatial computing—plus a surprise appearance from his personal AI agent Samir, who gave us a glimpse into the not-so-distant future.This episode offers a rare and dynamic cross-section of the global leaders building Web3's next chapter—combining infrastructure, policy, finance, and futuristic tech.Support us through our Sponsors! ☕

We love to hear from our listeners. Send us a message. On this week's episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing innovative solid tumor treatments that target functional proteins in the tumor micro-environment. Chetboun talks about raising money for preclinical research and navigating the valley of death between research and clinical development, accessing French innovation funding and angel networks, how click chemistry can produce therapies at a lower cost compared to antibody-drug conjugates (ADCs), and the potential use of drug combinations and umbrella trials for testing multiple cancer indications.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

"Education was the highest value in our family. It was not even a question—it was the core." In this episode of The Biotech Startups Podcast, Samir Khleif—Founder and CEO of Georgiamune—shares how his upbringing as a Middle Eastern refugee, in a family where education was everything, laid the foundation for his pioneering work in oncology and immunotherapy. Khleif recounts how formative experiences with his physicist father and the Boy Scouts instilled discipline, fairness, and a sense of adventure, shaping his leadership approach and fueling his journey from humble beginnings and early entry into medical school to spearheading innovative treatments that reprogram immune responses against cancer and autoimmune disease.

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company's ambitious pipeline and strategic direction.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Moderna CEO Stephane Bancel has stated that the company is not interested in pursuing mergers and acquisitions, preferring to focus on research and development partnerships instead. Former President Trump has threatened 17 big pharmaceutical companies with a deadline to lower drug prices or face government intervention. Regeneron faces regulatory issues affecting decision dates for high-dose Eylea, while Moderna has won a UK patent battle against Pfizer and BioNTech. After the removal of FDA chief Dr. Prasad, Dr. Makary is seeking better alignment between drug and biologic approvals at the agency. Alnylam's impressive sales of Amvuttra ATTR-CM have led to a surge in stock prices, while Merck is aiming to save $3 billion through job cuts. Moderna is also cutting 10% of its global workforce. Recent FDA approvals for myeloma and Alzheimer's treatments, as well as updates on layoffs and pipeline developments in the biotech industry are also making headlines.

Derek Champagne interviews Quang X. Pham. Quang is a biotech executive, war veteran, author, speaker, and community leader with a remarkable journey shaped by resilience, service, and entrepreneurship. He made history as the first Vietnamese American to earn naval aviator wings in the Marine Corps and lead an initial public offering (IPO) on Nasdaq.His inspiring American underdog journey, told in first person, is unlike any other. Born in Saigon, South Vietnam, Quang and his family fled as refugees when he was 10, while his father, a Republic of Vietnam Air Force pilot,remained and was imprisoned for more than a decade. After earning a degree from UCLA, Quang served seven years on active duty, flying CH-46 helicopters in the Persian Gulf War, Somalia, and the Reserves. Following his military career, Quang transitioned into business, founding multiple pharmaceutical companies. In 2000, he launched MyDrugRep.com (which became LathianSystems), an innovative online platform for physician marketing engagements, which was later acquired. In 2015, he founded Espero Pharmaceuticals and Jacksonville Pharmaceuticals. His leadership and entrepreneurial success earned him the Florida EY Entrepreneur of the Year Award in 2018. Today Quang serves as Chairman and CEO, Cadrenal Therapeutics (Nasdaq: CVKD).Quang is also the author of the award-winning father-son memoir, A Sense of Duty: Our Journe y from Vietnam (Penguin Random House), and his new book, Underdog Nation: Zero In on Effort and Results for Success (Forbes Books).Committed to giving back, Quang has served on the boards of private companies, veterancharities and educational organizations. He lives in Florida with his family, continuing tolead and inspire.Order Quang's new book here: https://quangxpham.com/books/Business Leadership Series Intro and Outro music provided by Just Off Turner: https://music.apple.com/za/album/the-long-walk-back/268386576

Markets sell off after a weak July Jobs Report and news of Trump's revised reciprocal tariffs, but Jefferies Chief Market Strategist David Zervos says not to be alarmed. Plus, Amazon sinks on yesterday's rough forecast while burgers and biotech rally. Fast Money Disclaimer

In this special episode of Grow Everything, hosts Karl and Erum pull back the curtain on their own operations, offering a behind-the-scenes look at how the podcast came to life. They discuss the core mission of sharing innovative bioengineering breakthroughs, the challenges of maintaining a weekly podcast, and the team behind it all. From the technical intricacies of biomanufacturing to the strategic communications needed to make those breakthroughs accessible to a wider audience, this episode reflects on the journey, growth, and impact of the Grow Everything platform. With a mix of humor and passion for sustainability, Erum and Karl continue their mission to educate and inspire those working at the cutting edge of synthetic biology and the bioeconomy.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:00:00:00 - Kicking Off the Conversation: What's on the Horizon?00:00:13 - Welcome to the Grow Everything Podcast: Let's Dive In!00:00:29 - Taking You Inside Grow Everything: A Glimpse Behind the Curtain00:01:03 - From Idea to Reality: How the Podcast Came to Life00:04:27 - The Roadblocks, the Breakthroughs: What's Shaped Our Journey00:06:24 - Crafting the Perfect Biotech Story: Marketing with Purpose00:08:08 - Changing the Game: How Our Guests Redefine the Future00:17:11 - Hot Takes on Biotech: What's Overhyped and What's Real?00:19:30 - How to Connect with Founders: Elevating Their Narrative00:21:15 - Uncovering Hidden Biotech Gems: The Innovators Who Deserve the Spotlight00:23:53 - The Power of the Podcast: How We Help Our Clients Shine00:27:48 - A Vision for 2030: Dream Guests and Big Ideas00:32:14 - Rapid Fire: Fun Facts, Favorites, and More!00:36:12 - Wrapping Up: A Peek at What's Next and Future GuestsLinks and Resources:⁠What's Your Biostrategy?MessaginglabAmplafy Media 90. Flipping the Light Switch on Cells: Deniz Kent of Prolific Machines116. Cell Yeah for Space!: Pioneer Labs' Erika DeBenedictis on Engineering Life for Mars93. Houston, We Have a Protocol: NASA's Kate Rubins on Biotech in Space76. Not Boring Century of Biotech with Elliot HershbergDavid De Lucreiza on LinkedInTopics Covered: science communications, podcast creation, podcast origin, biotech messaging, startupsHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

Synopsis: Amy Burroughs, CEO of Terns Pharmaceuticals, joins Alok Tayi to share how she's leading bold innovation in CML and obesity treatment, driving two high-stakes data readouts in 2025. From a non-linear path through tech, brand management, and Genentech to building resilient biotech teams, Amy reveals why product positioning, tolerability, and mentorship matter just as much as the science. She also shares her take on CEO loneliness, the value of a “personal board of directors,” and what it takes to lead with clarity, grit, and purpose in today's biotech landscape. Biography: Amy Burroughs joined as our Chief Executive Officer and a member of our Board of Directors in February 2024, bringing more than 25 years of leadership experience. Most recently, she served as CEO at Cleave Therapeutics, where she led the company through financings, spearheaded licensing and collaboration deals, and oversaw the clinical development of its investigational therapy, CB-5339, for the treatment of acute myeloid leukemia. Previously, she served as executive in residence at 5AM Ventures and, in parallel, as senior advisor to one of its portfolio companies, Crinetics Pharmaceuticals, during its initial public offering. Earlier in her career, Ms. Burroughs held roles of increasing responsibility in commercial and strategy at Genentech, commercial and business development at other high growth therapeutics companies, talent and governance at Egon Zehnder International, and brand management at Procter & Gamble. Ms. Burroughs earned her M.B.A. from Harvard Business School, where she graduated as a Baker Scholar, and her B.A. in computer science with a minor in economics from Dartmouth College. She is currently a member of the board and audit committees at Tenaya Therapeutics.

In this episode of Data in Biotech, Yaron David, CTO and Co-Founder of BioRaptor, joins host Ross Katz to explore how biotech companies can gain a holistic view of bioprocessing through real-time data integration, visualization, and modeling. Learn how BioRaptor's full-stack platform helps scientists replace clunky spreadsheets with actionable insights—accelerating experiments and optimizing yields. ​​What You'll Learn in This Episode: >> Why Excel is holding back innovation in bioprocessing labs >> How BioRaptor enables holistic bioprocess understanding across experiments >> The role of virtual sensors in enhancing real-time data visibility >> How BioRaptor drives ROI by onboarding customers in weeks, not months >> The difference between operational and optimization AI in biotech Meet Our Guest Yaron David is CTO and Co-Founder of BioRaptor, an AI-powered analytics platform transforming bioprocess data into scientific insights. With an MD and PhD in neuroscience, he blends medical, software, and startup experience to revolutionize data infrastructure for biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about BioRaptorConnect with Yaron David on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Join us as we explore the exciting world of biotech business strategy and innovation. Learn how top companies are using new strategies and technologies to succeed. Whether you're experienced or just starting out, this episode offers practical insights to help you thrive in the biotech industry. Tune in for a straightforward guide to innovation in biotech!

Live from Proof of Talk Paris 2025, this special episode of The Edge of Show dives deep into the explosive convergence of AI, blockchain, and decentralized infrastructure.We sat down with three visionary companies shaping the future of artificial intelligence and machine economies. First we spoke with Humayun Sheikh, the CEO of Fetch.ai, he breaks down the launch of ASI One and explains how agent-based AI is reshaping everything from enterprise tools to decentralized infrastructure. Next we welcomed back Janet Adams, the COO of SingularityNet and Co-Founder of the Artificial Superintelligence Alliance. she offers a bold vision for decentralized AGI, diversity in AI development, and why she believes decentralized models will outperform big tech in the coming AI arms race. And lastly the co-founders of Peaq, Leonard Dorlöchter & Till Wendler, join us to discuss how machines are starting to own and operate assets, collaborate across borders, and drive real-world revenue in smart cities around the world.This episode is packed with insight, strategy, and optimism about how AI and decentralization are shaping the next decade of global innovation.Support us through our Sponsors! ☕

A handful of encouraging signals is cause for cautious optimism for biotech headed into the second half of the year — companies have been able to parlay strong data into follow-on capital and M&A activity is picking up. That said, the IPO market continues to be closed and concerns about U.S. drug pricing and FDA stability continue to weigh on expectations for a robust near-term sector recovery.Special guest Megan Hooton from IQVIA Biotech joins BioCentury's analysts on a special edition of the podcast to discuss key indicators of progress for the biopharma sector. Hooton is president of IQVIA Biotech, which sponsored this episode of the pod.View full story: https://www.biocentury.com/article/656614#biotech #biopharma #pharma #lifescience #BiotechTrends #ClinicalTrials #GeneTherapy #CellTherapy00:01 – Sponsor Message: IQVIA Biotech02:37 – Biotech Markets06:41 – Clinical Highlights10:26 – Insights from Meg Hooton23:10 – Advanced TherapiesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Lexi Silver is 15 years old. She lost both of her parents before she turned 11. That should tell you enough—but it doesn't. Because Lexi isn't here for your pity. She's not a sob story. She's not a trauma statistic. She's a writer, an advocate, and one of the most emotionally intelligent people you'll ever hear speak into a microphone.In this episode, Lexi breaks down what grief actually feels like when you're a kid and the adults around you just don't get it. She talks about losing her mom on Christmas morning, her dad nine months later, how the system let her down, and how Instagram trolls tell her she's faking it for attention. She also explains why she writes, what Experience Camps gave her, how she channels anger into poems, and what to say—and not say—to someone grieving.Her life isn't a Netflix drama. But it should be.And by the way, she's not “so strong.” She's just human. You'll never forget this conversation.RELATED LINKS• Lexi on Instagram: @meet.my.grief• Buy her book: The Girl Behind Grief's Shadow• Experience CampsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week's deal between GSK and Jiangsu Hengrui is a prime example of how Western biopharmas have begun to recognize the innovation and opportunities being fostered in China — and how it's no longer all about fast followers.On the latest BioCentury This Week podcast, BioCentury's analysts put the collaboration between GSK and Jiangsu Hengrui Pharmaceuticals, two of the most active cross-border dealmakers, into the context of East-West dealmaking over the past 30 months, assessing the innovation that is driving the rush to partner with biotechs in China, Japan, South Korea and beyond, and the types of companies looking to Asia for assets.BioCentury's analysts also discuss Steve Bates' outsized role in building the U.K. biotech hub, as he readies to take on a new role in the U.K. government. They examine new VC funds from Omega Funds and Brandon Capital, FDA's new national priority voucher pilot program, and fallout from how FDA and  Sarepta Therapeutics handled the deaths of four patients who had received the biotech's gene therapies. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656592#biotech #biopharma #pharma #lifescience #EastWestDealmaking #ChinaBiotech #UKBiotech #FDAPolicy00:01 - Sponsor Message: IQVIA Biotech02:48 - Asia Deals Landscape17:32 - Steve Bates & U.K. Biotech25:46 - FDA's New Voucher Pilot31:01 - New VC Funds35:28 - SareptaTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

We love to hear from our listeners. Send us a message. On this week's episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing  a radiopharmaceutical company focused on oncology. Dr. Delpassand discusses the current trends in radiopharmaceutical drug development, the differences between alpha- and beta-emitting isotopes, overcoming manufacturing and supply chain challenges and restraints, and building strategic partnerships with companies like Curium, Fusion (now part of AstraZeneca), and Sanofi. He also offers specific advice to physician-entrepreneurs interested in building their own drug development companies. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

As AI infiltrates every aspect of our lives, who are some of the people behind this huge inflection point? In this special three-part series, you'll hear from the people predicting and shaping our tech future. Host Manoush Zomorodi reports on the latest and revisits her favorite conversations with the minds crafting the digital world we live in today: what they've gotten right — and wrong — and where they think we're headed next. Part 3 features biochemist Jennifer Doudna, neurologist Tom Oxley and legal scholar Nita Farahany.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Join us for an exciting episode of The Edge of Show, live from Inscribing Vegas! In this episode, we dive deep into the intersection of art, technology, and the Bitcoin ecosystem. We kick off with Postwook, a lens-based mixed media artist, who shares insights about her unique approach to art using astronomical data and the significance of her work being displayed on the world's largest screen, the Sphere. Next, we chat with Marvin from Maestro, a blockchain infrastructure provider focused on UTXO blockchains. Then Sailor Gary, the CEO of Spirit Punks, the meme‑driven vodka company with blockchain swagger. Finally, we hear from Stephen Miller, who talks about his curated digest of the art world and his own collection, Behold. Support us through our Sponsors! ☕

Join us in this episode of Skin Anarchy as Dr. Ekta Yadav sits down with Ohad Bendror, founder and CEO of NanoSpun Technologies, to explore one of the most radical shifts in skincare: living, on-demand microbiome delivery. While most brands tout probiotics with shelf-stable claims, NanoSpun is building something entirely different—a biological platform that brings real, live cells directly to your skin.Ohad reveals how NanoSpun's technology works like a biotech engine—activating 100 billion+ live bacteria only when it hits your skin, preserving potency like “freshly squeezed juice.” It's not just delivery—it's a living factory in a face mask.This isn't about trends—it's about disrupting four major layers of the skincare model: real live cells, shelf-stable dormancy, on-demand activation, and functional delivery systems. The result? Postbiotics synthesized in real time, tailored to skin concerns like acne, aging, or sensitivity.NanoSpun isn't just a brand—it's a platform. From white-labeled partnerships to its in-house line Biotica 1905, it's redefining what skincare can do. Clinical results show improvements in hydration, redness, and fine lines in just weeks.If you've ever wondered what comes after serums and synthetics—this is it. Tune in to hear how NanoSpun is building the biological infrastructure of beauty and why the future of skincare is very much alive.CHAPTERS:(0:00) Introduction to NanoSpun and Ohad Bendror(1:03) The Birth of NanoSpun and Its Core Technology(2:30) Explaining Postbiotics and Their Relevance in Skincare(4:46) The Four-Layer Disruption: A New Approach to Skin Microbiome(7:51) Solving the Shelf Life Problem and Maintaining Bioavailability(9:57) The Role of Live Cell Technology in Skincare(14:03) Scaling and Customization: How NanoSpun Works for Different Skin Needs(19:19) The Future of Personalized Skincare with NanoSpun and AI(27:06) The Long-Term Roadmap and Potential of NanoSpun TechnologyTo learn more about NanoSpun, visit their website and social media.Learn more about Function Health and join using our link. The first 1000 get a $100 credit toward their membership. Visit www.functionhealth.com/SKINANARCHY or use gift code SKINANARCHY at sign-up to own your health.Please fill out this survey to give us feedback on the show!Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

A surge in private market investment has Fools wondering: is it time to bet bigger on biotech? Tim Beyers and Karl Thiel discuss: - The rise in biotech funding from VCs and wealthy individuals. - The key attributes of an investable biotech. - Which is the better biotech: Viking Therapeutics or Eli Lilly? Companies discussed: VKTX, LLY, MRK Host: Tim Beyers and Karl Thiel Producer: Anand Chokkavelu Engineer: Dan Boyd, Natasha Hall Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement.Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices